[20 years of cardiovascular epidemiology. The clinician's viewpoint].
Over the last twenty years, several important clinical trials have brought major advances in the field of prevention and treatment of cardiovascular diseases. Fibrinolytic drugs, ACE inhibitors, new antiplatelet drugs or new tools in the field of interventional cardiology have been studied and have changed the daily practice of the cardiologists. Several remarks and comments are proposed with regards of these trials.
Bertrand
M E
ME
Service de Cardiologie B et Hémodynamique, Hôpital Cardiologique, Lille.
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002309:Cardiology / Q000639:trends; D002317:Cardiovascular Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000517:prevention & control* / Q000628:therapy; D002986:Clinical Trials as Topic; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D015912:Thrombolytic Therapy
D000806:Angiotensin-Converting Enzyme Inhibitors; D002317:Cardiovascular Agents; D000960:Hypolipidemic Agents; D010975:Platelet Aggregation Inhibitors